ArticleCancers2021
Treatments and Outcomes in Stage I Extranodal Marginal Zone Lymphoma in the United States.
Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 13 citations in OpenAlex.
- Primary Spinal Marginal Zone Lymphoma Presenting With Spinal Cord Compression: A Case Report.Cureus · 2026Article
- Field-testing the MALT-IPI in a single-center real-world cohort of patients with extranodal marginal zone lymphoma.Blood advances · 2026Article
- Observational
- SOHO State of the Art Updates and Next Questions | Current and Emerging Novel Treatments for Marginal Zone Lymphoma.Clinical lymphoma, myeloma & leukemia · 2026Review
- Peripheral blood involvement in extra-nodal marginal zone lymphoma.British journal of haematology · 2026Article
- Mucosal-Associated Lymphoid Tissue Lymphoma in Southeast Asia: A 15-Year Retrospective Multicenter Study.Hematology reports · 2025Article
- Impact of Age on Biology, Presentation and Outcomes in Marginal Zone Lymphoma: Results From a Multicenter Cohort Study.Hematological oncology · 2025Article
- Enhancing prognostication and personalizing treatment of extranodal marginal zone lymphoma.Expert review of hematology · 2023Review
- Predictors of survival in patients with MALT lymphoma: a retrospective, case-control study.Blood advances · 2023Review
- Top Ten Lymphoproliferative Lesions Not to Miss When Evaluating Oral Ulcer Biopsies.Head and neck pathology · 2023Review
- Revised MALT-IPI: A new predictive model that identifies high-risk patients with extranodal marginal zone lymphoma.American journal of hematology · 2022Article
- An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma.Blood advances · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
A considerable number of patients with extranodal marginal zone lymphoma (EMZL) are diagnosed with stage I disease. Information on treatments and survival by primary location remains limited. We extracted data from the Surveillance, Epidemiology, and End Results (SEER) database to assess treatment, primary location, and survival of patients with stage I EMZL. Results show that 7961 patients met inclusion criteria. Observation (no treatment) was the most common approach (31%) followed by radiation therapy (RT, 23%). The median overall survival (OS) was 17.3 years (95%CI 16.3 to 18.3). Shorter survival was observed in patients with stage I EMZL compared to expected survival in a cohort derived from the general U.S. population matched by sex, age, and calendar year at diagnosis. However, similar survival was observed in RT-treated patients. We identified age ≥ 60 years (SHR = 4.00, 95%CI 3.10-5.15;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.